Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 15/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24118075 | 0.82 | USP36 (0.45) | SMN1; SMN2LMNA | |
| SCHEMBL24118232 | 0.80 | EPHX2 (0.43) | — | |
| SCHEMBL24118337 | 0.80 | SMN1; SMN2 (0.41) | GCGRSMN1; SMN2NPC1ALDH1A1GAA | |
| SCHEMBL24117957 | 0.79 | GCGR (0.46) | GCGRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL24118074 | 0.79 | SMN1; SMN2 (0.41) | GCGRSMN1; SMN2NPC1ALDH1A1GAA | |
| SCHEMBL24118250 | 0.79 | ALDH1A1 (0.54) | LMNAALDH1A1RAB9A | |
| SCHEMBL24118252 | 0.79 | GCGR (0.38) | GCGRSMN1; SMN2NPC1ALDH1A1GAA | |
| SCHEMBL24118187 | 0.78 | IDO1 (0.56) | GCGRSMN1; SMN2LMNAALDH1A1GAA | |
| SCHEMBL24118233 | 0.78 | IDO1 (0.56) | GCGRSMN1; SMN2LMNAALDH1A1GAA | |
| SCHEMBL19316520 | 0.78 | P4HTM (0.58) | SMN1; SMN2NPC1ALDH1A1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | GCGR 3754/4885SMN1; SMN2 2675/4885LMNA 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.